How have IMUC shares performed in 2024?

EOM Pharmaceuticals' stock was trading at $0.2320 on January 1st, 2024. Since then, IMUC shares have decreased by 14.7% and is now trading at $0.1979. View the best growth stocks for 2024 here .

How were EOM Pharmaceuticals' earnings last quarter?

EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) announced its quarterly earnings results on Monday, August, 13th. The company reported ($0.01) earnings per share for the quarter.

How do I buy shares of EOM Pharmaceuticals?

Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IMUC

EOM Pharmaceuticals (IMUC) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free IMUC Stock Alerts

$0.20

+0.02 (+11.24%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.20
▼
$0.20
50-Day Range: $0.11
▼
$0.30
52-Week Range: $0.11
▼
$0.40

Volume: 212 shs
Average Volume: 3,884 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings Short Interest

Get EOM Pharmaceuticals alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About EOM Pharmaceuticals Stock (OTCMKTS:IMUC)

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

IMUC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMUC Stock News Headlines

April 19, 2024 | americanbankingnews.com

EOM Pharmaceuticals (OTCMKTS:IMUC) Shares Up 17.3%

January 5, 2024 | uk.finance.yahoo.com

ImmunoCellular Therapeutics, Ltd. (IMUC)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

December 29, 2023 | wsj.com

EOM Pharmaceutical Holdings Inc.

November 7, 2023 | finance.yahoo.com

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

November 4, 2023 | markets.businessinsider.com

IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years

November 3, 2023 | msn.com

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

November 1, 2023 | morningstar.com

Oramed Pharmaceuticals Inc ORMP

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

October 11, 2023 | markets.businessinsider.com

Analyst Ratings for Olema Pharmaceuticals

September 6, 2023 | finance.yahoo.com

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

August 17, 2023 | uk.finance.yahoo.com

Q2 2023 PAVmed Inc Earnings Call

August 3, 2023 | msn.com

EOM Pharmaceuticals shelves plans to uplist shares, raise $15M

July 17, 2023 | benzinga.com

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

July 3, 2023 | marketwatch.com

Amneal Pharmaceuticals: FDA Requests Additional Information on IPX203 Ingredient

June 14, 2023 | marketwatch.com

Amneal Pharmaceuticals Gets FDA Approval for Injectable Tumor Treatment

May 16, 2023 | msn.com

Trade commission fights Amgen's $28B purchase of Horizon Therapeutics

May 10, 2023 | msn.com

Pharma CEOs to testify in U.S. Senate hearing on insulin prices

May 10, 2023 | marketwatch.com

8-K: Acumen Pharmaceuticals, Inc.

May 9, 2023 | msn.com

Olema Pharmaceuticals GAAP EPS of -$0.70 misses by $0.04

May 9, 2023 | investing.com

OliX Pharmaceuticals Inc (226950)

March 30, 2023 | msn.com

USFDA gives final nod to Alembic Pharmaceuticals’ Glaucoma drug

March 27, 2023 | reuters.com

U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents

March 13, 2023 | marketwatch.com

Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains

March 11, 2023 | finance.yahoo.com

EOM Pharmaceuticals Holdings, Inc. (IMUC)

February 24, 2023 | seekingalpha.com

Ionis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call Transcript

December 8, 2022 | technews.tmcnet.com

AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

See More Headlines

Receive IMUC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EOM Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/13/2018
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:IMUC
CUSIP: N/A
CIK: 822411
Web: www.imuc.com
Phone: (201) 351-0605
Fax: 818-224-5287
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.37

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Irach B. Taraporewala B.S. (Age 68)
M.S., Ph.D., CEO, President & Director
Comp: $265.65k
Mr. Wayne I. Danson CPA (Age 70)
CFO & Treasurer
Comp: $150k
Mr. Eli Goldberger (Age 34)
Founder, Chairman & COO
Dr. Shalom Z. Hirschman M.D. (Age 88)
Co-Founder, Chief Scientific Officer & Medical Director

Key Competitors

View All Competitors

IMUC Stock Analysis - Frequently Asked Questions

How have IMUC shares performed in 2024?: EOM Pharmaceuticals' stock was trading at $0.2320 on January 1st, 2024. Since then, IMUC shares have decreased by 14.7% and is now trading at $0.1979.
View the best growth stocks for 2024 here.
How were EOM Pharmaceuticals' earnings last quarter?: EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) announced its quarterly earnings results on Monday, August, 13th. The company reported ($0.01) earnings per share for the quarter.
How do I buy shares of EOM Pharmaceuticals?: Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMUC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial